Concord Biotech Limited IPO

Concord Biotech Limited Incorporated in 1984, Company is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.

Concord Biotech is a niche biopharma company manufacturing APIs (active pharmaceutical ingredients) and formulations for select therapeutic areas. Operating in the B2B segment, it develops

(a) APIs through fermentation as well as semi-synthetic processes, across therapeutic areas of immunosuppressants, oncology, and anti-infectives.

(b) formulations, which are used in the therapeutic areas of immunosuppressants, nephrology drugs, and anti-infective drugs for critical care.

The company had submitted 128 Drug Master Files (DMFs) for their APIs in multiple countries. These filings consisted of 20 DMFs in the United States, 65 in Europe, and 4 in Japan.

Concord Biotech has close to equal market share in domestic as well as export markets (catering to 70+ countries), with the United States being a key export market. It has a diversified customer base (200+ with Intas Pharmaceuticals and Glenmark Pharmaceuticals being 2 major customers) and long-standing relationships with various global generic pharmaceutical companies.

Concord Biotech possesses three manufacturing facilities (Dholka, Valthera, Limbasi) with a combined fermentation capacity of 1,250 m3 and two dedicated research and development (R&D) units, all situated in Gujarat, India. It adheres to regulations and quality standards set by authorities in India and other regions.

APPLY IN IPO